Thomasville National Bank Sells 577 Shares of Eli Lilly and Company $LLY

Key Points

• Thomasville National Bank reduced its holdings in Eli Lilly and Company by 14.3% during the second quarter, selling 577 shares and maintaining a total ownership of 3,451 shares valued at approximately $2.69 million.
• Eli Lilly recently announced a $1.50 quarterly dividend, which provides an annualized yield of 0.8%, with a payout ratio of 39.22%.
• The company's latest earnings report showed a significant beat on expectations, with $6.31 EPS compared to estimates of $5.59, and quarterly revenue of $15.56 billion, reflecting a 37.6% year-over-year increase.

Thomasville National Bank decreased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 14.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 3,451 shares of the company's stock after selling 577 shares during the quarter. Thomasville National Bank's holdings in Eli Lilly and Company were worth $2,690,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in LLY. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter worth about $27,000. Citizens National Bank Trust Department grew its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company during the first quarter worth about $40,000. Finally, Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company during the fourth quarter worth about $43,000. Institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on LLY. Guggenheim decreased their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Finally, Leerink Partners reiterated a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $939.61.

Eli Lilly and Company Stock Up 0.4%

Eli Lilly and Company stock traded up $3.33 during mid-day trading on Monday, reaching $755.32. The company's stock had a trading volume of 2,520,625 shares, compared to its average volume of 4,097,630. The business's 50 day simple moving average is $738.37 and its 200 day simple moving average is $769.80. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $939.30. The company has a market capitalization of $714.88 billion, a price-to-earnings ratio of 49.37, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the firm posted $3.92 EPS. The company's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director directly owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.14% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.